Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1beta in Patients With Chronic Systolic Heart Failure.

Next Previous
Search
Trial Profile

A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1beta in Patients With Chronic Systolic Heart Failure.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Recombinant human neuregulin 1-beta (Primary)
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Sponsors Zensun (Shanghai) Sci & Tech

    • Most Recent Events

    • 18 Jul 2012 Planned End Date changed from 1 Jul 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 18 Jul 2012 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 21 Sep 2011 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top